Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medicare CAR-T Payment Policy Walks Line Between Innovation and Cost Concerns

Executive Summary

CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement. 

You may also be interested in...



Medicare And CAR-Ts: Breyanzi Denied Add-On Payments But Tecartus, Abecma Approved

CMS shows willingness to continue approving new technology add-on payments for CAR-T treatments despite suggestions they are no longer needed.

As CAR-Ts Proliferate, CMS Seeks To Reserve Medicare Add-On Payments For ‘New’ Therapies

Products from Bristol-Myers Squibb, Gilead and J&J might be eligible for supplemental reimbursement under hospital payment proposed rule that could help promote uptake.

BMS/Bluebird Ready Abecma, First BCMA-Targeting CAR-T, For Initial Patients

Idecabtagene vicleucel for fifth-line multiple myeloma lags GSK’s BCMA-targeting ADC Blenrep, but it is months ahead of J&J/Legend’s CAR-T. Abecma is BMS’s second CAR-T approval this year.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS142185

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel